Cargando…
Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
Background: There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531872/ https://www.ncbi.nlm.nih.gov/pubmed/37754797 http://dx.doi.org/10.3390/jcdd10090368 |
_version_ | 1785111822405206016 |
---|---|
author | Saraç, İbrahim Aydın, Sidar Şiyar Özmen, Murat Doru, Halil İbrahim Tonkaz, Gökhan Çırçır, Melike Nur Akpınar, Furkan Zengin, Onur Delice, Orhan Aydınyılmaz, Faruk |
author_facet | Saraç, İbrahim Aydın, Sidar Şiyar Özmen, Murat Doru, Halil İbrahim Tonkaz, Gökhan Çırçır, Melike Nur Akpınar, Furkan Zengin, Onur Delice, Orhan Aydınyılmaz, Faruk |
author_sort | Saraç, İbrahim |
collection | PubMed |
description | Background: There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late clinical outcomes, and management of PE in COVID-19. Materials and Methods: Between August 2020 and March 2021, 15,689 patients were followed up in our pandemic hospital due to COVID-19. Patients with positive polymerase chain reaction (PCR) test results and PE associated with COVID-19 in computed tomography (CT) were included in the study. The patients were divided into three groups according to PE size (mild, moderate, and large). Transthoracic echocardiography (TTE) records, laboratory data, clinical outcomes, and medical treatments of patients discharged from the hospital were retrospectively reviewed. Results: According to the PE size (mild, moderate, large) of 256 patients with PE at admission or discharge, the mean age was 62.17 ± 16.34, 69.12 ± 12.52, and 72.44 ± 15.26, respectively. The mean follow-up period of the patients was 25.2 ± 5.12 months. Of the patients in the study population, 53.5% were in the mild group, 30.4% in the moderate group, and 16.1% in the large group. PE became chronic in a total of 178 (69.6%) patients at the end of the mean three months, and chronicity increased as PE size increased. Despite the different anti-inflammatory treatments for PE in the acute phase, similar chronicity was observed. In addition, as the PE size increased, the patients’ frequency of hospitalization, complications, and mortality rates showed statistical significance between the groups. Conclusions: The clinical prognosis of patients presenting with PE was quite poor; as PE in size increased, cardiac and noncardiac events and mortality rates were significantly higher. Patients with large PE associated with COVID-19 at discharge should be monitored at close intervals due to the chronicity of PE and the increased risk of tamponade. |
format | Online Article Text |
id | pubmed-10531872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105318722023-09-28 Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 Saraç, İbrahim Aydın, Sidar Şiyar Özmen, Murat Doru, Halil İbrahim Tonkaz, Gökhan Çırçır, Melike Nur Akpınar, Furkan Zengin, Onur Delice, Orhan Aydınyılmaz, Faruk J Cardiovasc Dev Dis Article Background: There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late clinical outcomes, and management of PE in COVID-19. Materials and Methods: Between August 2020 and March 2021, 15,689 patients were followed up in our pandemic hospital due to COVID-19. Patients with positive polymerase chain reaction (PCR) test results and PE associated with COVID-19 in computed tomography (CT) were included in the study. The patients were divided into three groups according to PE size (mild, moderate, and large). Transthoracic echocardiography (TTE) records, laboratory data, clinical outcomes, and medical treatments of patients discharged from the hospital were retrospectively reviewed. Results: According to the PE size (mild, moderate, large) of 256 patients with PE at admission or discharge, the mean age was 62.17 ± 16.34, 69.12 ± 12.52, and 72.44 ± 15.26, respectively. The mean follow-up period of the patients was 25.2 ± 5.12 months. Of the patients in the study population, 53.5% were in the mild group, 30.4% in the moderate group, and 16.1% in the large group. PE became chronic in a total of 178 (69.6%) patients at the end of the mean three months, and chronicity increased as PE size increased. Despite the different anti-inflammatory treatments for PE in the acute phase, similar chronicity was observed. In addition, as the PE size increased, the patients’ frequency of hospitalization, complications, and mortality rates showed statistical significance between the groups. Conclusions: The clinical prognosis of patients presenting with PE was quite poor; as PE in size increased, cardiac and noncardiac events and mortality rates were significantly higher. Patients with large PE associated with COVID-19 at discharge should be monitored at close intervals due to the chronicity of PE and the increased risk of tamponade. MDPI 2023-08-27 /pmc/articles/PMC10531872/ /pubmed/37754797 http://dx.doi.org/10.3390/jcdd10090368 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Saraç, İbrahim Aydın, Sidar Şiyar Özmen, Murat Doru, Halil İbrahim Tonkaz, Gökhan Çırçır, Melike Nur Akpınar, Furkan Zengin, Onur Delice, Orhan Aydınyılmaz, Faruk Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
title | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
title_full | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
title_fullStr | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
title_full_unstemmed | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
title_short | Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 |
title_sort | prevalence, risk factors, prognosis, and management of pericardial effusion in covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531872/ https://www.ncbi.nlm.nih.gov/pubmed/37754797 http://dx.doi.org/10.3390/jcdd10090368 |
work_keys_str_mv | AT saracibrahim prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT aydınsidarsiyar prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT ozmenmurat prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT doruhalilibrahim prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT tonkazgokhan prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT cırcırmelikenur prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT akpınarfurkan prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT zenginonur prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT deliceorhan prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 AT aydınyılmazfaruk prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19 |